How big is Accelerate Diagnostics, Inc.?

As of Jun 18, Accelerate Diagnostics, Inc. has a market capitalization of $0.22 million, with net sales of $11.71 million and a net profit of -$50.05 million over the last four quarters. Shareholder's funds are reported at -$56.04 million, and total assets amount to $28.56 million.

As of Jun 18, Accelerate Diagnostics, Inc. has a market capitalization of 0.22 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 11.71 million, while the sum of net profit for the same period is -50.05 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -56.04 million, and total assets amount to 28.56 million.

What does Accelerate Diagnostics, Inc. do?

Accelerate Diagnostics, Inc. is an in vitro diagnostics company focused on improving patient outcomes through the diagnosis of serious infections. As of December 2024, it reported net sales of $3 million and a net loss of $10 million, with a market cap of $0.22 million.

Overview: <BR>Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 3 Million (Quarterly Results - Dec 2024) <BR>Most recent Net Profit: -10 Million (Quarterly Results - Dec 2024) <BR>Market-cap: USD 0.22 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.85 <BR>Return on Equity: 85.67% <BR>Price to Book: -0.00<BR><BR>Contact Details: <BR>Address: 3950 S. Country Club Road #470, Building 3-307 TUCSON AZ : 85714-2240 <BR>Tel: 1 303 8638088 <BR>Fax: 1 302 6555049 <BR>Website: http://acceleratediagnostics.com/

Who are in the management team of Accelerate Diagnostics, Inc.?

As of March 2022, the management team of Accelerate Diagnostics, Inc. includes Mr. John Patience (Independent Chairman), Mr. John Phillips (CEO and COO), and several Independent Directors: Mr. Thomas Brown, Mr. Roland Diggelmann, Ms. Louise Francesconi, Mr. Mark Miller, and Mr. Jack Schuler. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of Accelerate Diagnostics, Inc. includes the following individuals:<BR><BR>- Mr. John Patience, Independent Chairman of the Board<BR>- Mr. John Phillips, Chief Executive Officer, Chief Operating Officer, and Director<BR>- Mr. Thomas Brown, Independent Director<BR>- Mr. Roland Diggelmann, Independent Director<BR>- Ms. Louise Francesconi, Independent Director<BR>- Mr. Mark Miller, Independent Director<BR>- Mr. Jack Schuler, Independent Director<BR><BR>This team oversees the strategic direction and operations of the company.

Should I buy, sell or hold Accelerate Diagnostics, Inc.?

Is Accelerate Diagnostics, Inc. overvalued or undervalued?

As of August 3, 2017, Accelerate Diagnostics, Inc. is considered risky and overvalued due to negative valuation ratios and a year-to-date return of -100.0%, significantly underperforming the S&P 500's 12.22% return.

As of 3 August 2017, the valuation grade for Accelerate Diagnostics, Inc. moved from does not qualify to risky, indicating a deterioration in its financial standing. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -0.01 and an EV to Sales ratio of 4.11, which suggests that investors are paying a high price relative to the company's sales. Additionally, the EV to EBITDA ratio stands at -1.51, further highlighting the company's financial struggles.<BR><BR>In comparison to its peers, Accelerate Diagnostics, Inc. has a P/E ratio of 0.0000, while Clearpoint Neuro, Inc. has a P/E of -13.9815 and Stereotaxis, Inc. has a P/E of -11.2314, all indicating a challenging environment for companies in this sector. The stock has underperformed significantly, with a year-to-date return of -100.0% compared to the S&P 500's return of 12.22%, reinforcing the notion that the company is currently overvalued.

Is Accelerate Diagnostics, Inc. technically bullish or bearish?

As of July 7, 2025, Accelerate Diagnostics, Inc. shows a mildly bearish trend with mixed technical indicators, having returned -100% over various time frames, significantly underperforming the S&P 500.

As of 7 July 2025, the technical trend for Accelerate Diagnostics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators showing mixed signals. The MACD is mildly bullish on both weekly and monthly time frames, while the moving averages indicate a bearish trend on the daily. The Bollinger Bands are sideways weekly but mildly bearish monthly, and both KST and Dow Theory show bearish and no trend signals, respectively. <BR><BR>In terms of performance, the stock has returned -100% over the past month, year-to-date, year, three years, five years, and ten years, significantly underperforming the S&P 500, which has returns of 2.33%, 12.22%, 17.14%, 70.41%, 96.61%, and 231.64% in the same periods.